KIT and neoplasm: The third one got cytokine-induced killer cells (CIKs) from KIT/PDGFRA-WT GIST patients in 2022, and found that patient-derived CIKs killed autologous imatinib- and sunitinib-resistant tumor cells either directly or indirectly [259].